BLU-701
not tagged
['sclc', 'lung', 'nsclc']
#cedarssinaicancer at #asco22. a phase 1/2 study of the highly selective egfr inhibitor, blu-701, in patients with egfr-mutant non small cell lung cancer with co-author dr. karen reckamp is being presented #nsclc 
Cedars-Sinai Cancer, ranked #9 in the nation in 2021 by U.S. News & World Report.